…
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
DaVita HealthCare Partners Inc operates a nationwide network of outpatient dialysis clinics and related clinical services for patients with chronic kidney disease, providing in-center and home dialysis support. Long-term growth may be supported by aging demographics and higher chronic kidney disease prevalence, rising adoption of home dialysis and value-based care programs, and scale that could support recurring revenue and operational efficiencies.
Primary risks include exposure to Medicare and commercial reimbursement and regulatory changes, labor and staffing shortages, and operational and compliance challenges inherent to dialysis services that investors should monitor.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 1346.82M | 1530.39M | 1177.09M | 966.28M | 1518.49M |
| Minority interest | -331.91M | -314.39M | -265.44M | 221.24M | 233.31M |
| Net income | 746.80M | 936.34M | 691.53M | 768.19M | 978.45M |
| Selling general administrative | 1673.63M | 1538.34M | 1473.98M | 1355.20M | 1195.34M |
| Gross profit | 3684.24M | 4217.03M | 3820.43M | 3400.34M | 3646.38M |
| Reconciled depreciation | 715.35M | 723.86M | 745.44M | 732.60M | 680.62M |
| Ebit | 1926.75M | 2000.86M | 1575.64M | 1339.06M | 1797.37M |
| Ebitda | 2642.10M | 2724.72M | 2321.09M | 2055.90M | 2484.36M |
| Depreciation and amortization | 715.35M | 723.86M | 745.44M | 716.84M | 686.99M |
| Non operating income net other | - | - | - | -15.77M | 6.38M |
| Operating income | 2010.62M | 2090.48M | 1602.78M | 1339.06M | 1797.37M |
| Other operating expenses | 11632.45M | 10725.07M | 10537.36M | 10297.35M | 9848.36M |
| Interest expense | 549.67M | 470.47M | 398.55M | 357.02M | 285.25M |
| Tax provision | 293.11M | 279.66M | 220.12M | 198.09M | 306.73M |
| Interest income | 579.93M | 470.47M | 398.55M | 357.02M | 285.25M |
| Net interest income | -579.93M | -470.47M | -398.55M | -357.02M | -285.25M |
| Extraordinary items | 25.00M | 0.00M | 0.00M | 13.45M | 0.00M |
| Income tax expense | 293.11M | 279.66M | 220.12M | 198.09M | 306.73M |
| Total revenue | 13643.07M | 12815.55M | 12140.15M | 11609.89M | 11618.80M |
| Total operating expenses | 1673.63M | 2126.55M | 2217.65M | 2087.80M | 1875.95M |
| Cost of revenue | 9958.82M | 8598.52M | 8319.72M | 8209.55M | 7972.41M |
| Total other income expense net | -663.79M | -560.09M | -425.69M | -372.78M | -278.88M |
| Discontinued operations | - | - | - | 13.45M | 13.45M |
| Net income from continuing ops | 1053.72M | 1250.74M | 956.98M | 768.19M | 1211.76M |
| Net income applicable to common shares | 746.80M | 936.34M | 691.53M | 560.40M | 978.45M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 17480.10M | 17285.27M | 16893.58M | 16928.25M | 17121.49M |
| Intangible assets | 222.12M | 197.43M | 203.22M | 182.69M | 177.69M |
| Other current assets | 156.28M | 235.38M | 187.22M | 78.84M | 165.58M |
| Total liab | 16321.66M | 15193.92M | 14150.23M | 14703.45M | 14750.51M |
| Total stockholder equity | 1158.44M | 2091.35M | 2743.35M | 712.33M | 755.51M |
| Deferred long term liab | - | - | - | 782.79M | 830.95M |
| Other current liab | 1910.80M | 2415.91M | 1581.48M | 730.38M | 709.35M |
| Common stock | 0.07M | 0.09M | 0.09M | 0.09M | 0.10M |
| Capital stock | 0.07M | 0.09M | 0.09M | 0.09M | 0.10M |
| Retained earnings | -328.43M | 1534.63M | 598.29M | 174.49M | 354.34M |
| Other liab | - | - | - | 888.02M | 950.11M |
| Good will | 7545.10M | 7375.22M | 7112.56M | 7076.61M | 7046.24M |
| Other assets | 246.52M | -115.02M | 725.90M | 0.00M | 136.68M |
| Cash | 757.75M | 794.93M | 380.06M | 244.09M | 461.90M |
| Cash and equivalents | 676.44M | 794.93M | 380.06M | 244.09M | 461.90M |
| Total current liabilities | 3141.63M | 2973.41M | 2642.21M | 2619.75M | 2398.53M |
| Current deferred revenue | - | - | 28.51M | 782.79M | 713.75M |
| Net debt | 14292.24M | 10590.62M | 10736.36M | 11578.40M | 11513.35M |
| Short term debt | 534.68M | 681.28M | 517.70M | 626.80M | 573.39M |
| Short long term debt | 109.20M | 270.87M | 123.30M | 231.40M | 179.03M |
| Short long term debt total | 12874.33M | 12066.84M | 11116.42M | 11822.49M | 11975.25M |
| Other stockholder equity | -199.94M | -1102.80M | 509.80M | 606.93M | 540.32M |
| Property plant equipment | 5210.15M | 5334.47M | 5574.90M | 3256.40M | 3479.97M |
| Total current assets | 4058.00M | 3746.07M | 3137.91M | 3155.29M | 3167.72M |
| Long term investments | 198.22M | 370.34M | 593.74M | 275.44M | 288.39M |
| Net tangible assets | - | - | - | -5198.06M | -5033.59M |
| Short term investments | 24.30M | 51.06M | 11.61M | 77.69M | 22.31M |
| Net receivables | 2959.04M | 2530.14M | 2415.91M | 2550.65M | 2410.51M |
| Long term debt | 10163.99M | 9175.90M | 8268.33M | 8692.62M | 8729.15M |
| Inventory | 160.63M | 134.56M | 143.10M | 109.12M | 107.43M |
| Accounts payable | 696.15M | 547.20M | 514.53M | 479.78M | 402.05M |
| Noncontrolling interest in consolidated entity | - | - | - | 163.57M | 180.64M |
| Accumulated other comprehensive income | -122.78M | -310.80M | -52.08M | -69.19M | -139.25M |
| Common stock total equity | - | - | - | 0.09M | 0.10M |
| Retained earnings total equity | - | - | - | 174.49M | 354.34M |
| Non currrent assets other | 246.52M | 261.73M | 271.25M | -467.20M | -694.28M |
| Non current assets total | 13422.10M | 13654.22M | 13755.67M | 13772.96M | 13953.76M |
| Capital lease obligations | 2601.14M | 2209.66M | 2330.39M | 2898.47M | 3067.07M |
| Long term debt total | 12339.65M | 11385.56M | 10598.72M | 8692.62M | 8729.15M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 29.70M | -771.43M | -816.77M | -83.60M | -14.70M |
| Change to liabilities | - | - | - | 172.27M | -110.49M |
| Total cashflows from investing activities | -654.95M | -771.43M | -771.80M | -630.35M | -784.73M |
| Net borrowings | 823.43M | 1109.10M | -552.62M | -11.28M | 754.25M |
| Total cash from financing activities | -1374.78M | -816.94M | -1170.49M | -1121.13M | -1082.97M |
| Change to operating activities | - | - | - | 85.87M | -14.82M |
| Net income | 1078.72M | 1250.74M | 691.53M | 781.64M | 1211.76M |
| Change in cash | -122.08M | 415.19M | 125.64M | -215.97M | 53.17M |
| Begin period cash flow | 879.83M | 464.63M | 338.99M | 554.96M | 501.79M |
| End period cash flow | 757.75M | 879.83M | 464.63M | 338.99M | 554.96M |
| Total cash from operating activities | 1886.50M | 2022.04M | 2059.03M | 1564.57M | 1930.88M |
| Issuance of capital stock | - | 20.45M | 16.90M | - | - |
| Depreciation | 715.35M | 723.86M | 745.44M | 732.60M | 680.62M |
| Other cashflows from investing activities | -36.34M | 32.54M | 35.52M | 56.68M | -128.57M |
| Dividends paid | - | - | - | 267.95M | 244.03M |
| Change to inventory | -19.95M | 17.94M | -32.13M | -0.76M | 5.72M |
| Change to account receivables | -210.63M | -29.77M | 172.36M | -148.39M | -138.14M |
| Sale purchase of stock | -1793.00M | -1385.93M | -272.22M | -839.60M | -1598.63M |
| Other cashflows from financing activities | -374.69M | -560.55M | -362.56M | 2122.86M | 1376.78M |
| Change to netincome | - | - | - | 50.22M | 179.14M |
| Capital expenditures | 575.86M | 555.44M | 567.99M | 603.43M | 641.47M |
| Change receivables | - | - | - | -120.86M | -9.48M |
| Cash flows other operating | - | - | - | -50.55M | -26.39M |
| Cash and cash equivalents changes | - | - | - | -186.91M | 63.18M |
| Change in working capital | -263.24M | -29.82M | 194.53M | 0.10M | -140.64M |
| Stock based compensation | 139.95M | 102.79M | 112.38M | 95.43M | 102.21M |
| Other non cash items | 129.15M | 32.31M | 354.50M | 30.47M | 16.45M |
| Free cash flow | 1310.64M | 1466.60M | 1491.05M | 961.14M | 1289.41M |
Sector: Healthcare Industry: Medical Care Facilities
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| DVA DaVita HealthCare Partners Inc |
-3.47 1.78% |
191.35 | 15.78 | 10.79 | 0.73 | 21.63 | 1.62 | 8.39 |
| HCA HCA Healthcare, Inc. |
-12.49 2.46% |
494.99 | 14.27 | 13.46 | 1.21 | 291.34 | 1.83 | 8.99 |
| THC Tenet Healthcare Corporation |
-3.13 1.09% |
283.33 | 10.08 | 12.66 | 0.96 | 4.57 | 1.43 | 5.80 |
| FSNUY Fresenius SE & Co KGaA ADR |
0.06 0.42% |
14.62 | 16.87 | 9.44 | 0.42 | 0.78 | 0.79 | 5.37 |
| JDHIY JD Health International Inc |
- -% |
5.28 | 62.50 | 35.97 | 0.30 | 2.32 | 0.16 | 3.90 |
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
| Name | Title | Year Born |
|---|---|---|
| Mr. Javier J. Rodriguez | CEO & Exec. Director | 1971 |
| Mr. Joel Ackerman | CFO & Treasurer | 1965 |
| Ms. Kathleen Alyce Waters | Chief Legal & Public Affairs Officer | 1968 |
| Mr. James O. Hearty | Chief Compliance Officer | 1969 |
| Mr. Michael David Staffieri | Chief Operating Officer of Kidney Care | 1974 |
| Mr. John D. Winstel | Chief Accounting Officer | 1971 |
| Mr. Jim Gustafson | VP of Investor Relations | NA |
| Mr. Kenneth Gardner Smith | Chief People Officer | 1981 |
| Mr. Atul Mathur | Exec. VP of Global Operations | NA |
| Dr. Abdulkareem Alsuwaida FRCPC, M.D., MSc | Chief Medical Officer - Saudi Operations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.